pak 104p has been researched along with EHS Tumor in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cao, S; Minderman, H; Rustum, YM; Scheper, RJ; Slovak, ML; Tóth, K; Vanhoefer, U | 1 |
1 other study(ies) available for pak 104p and EHS Tumor
Article | Year |
---|---|
PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cyclic P-Oxides; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Nicotinic Acids; Paclitaxel; Sarcoma, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |